Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 315

1.

Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy.

Branzoli F, Pontoizeau C, Tchara L, Di Stefano AL, Kamoun A, Deelchand DK, Valabrègue R, Lehéricy S, Sanson M, Ottolenghi C, Marjanska M.

Neuro Oncol. 2019 Feb 6. doi: 10.1093/neuonc/noz031. [Epub ahead of print]

PMID:
30726924
2.

Transcriptome-wide association study identifies new candidate susceptibility genes for glioma.

Atkins I, Kinnersley B, Ostrom QT, Labreche K, Il'yasova D, Armstrong GN, Eckel-Passow JE, Schoemaker MJ, Nöthen MM, Barnholtz-Sloan JS, Swerdlow AJ, Simon M, Rajaraman P, Chanock SJ, Shildkraut J, Bernstein JL, Hoffmann P, Jöckel KH, Lai RK, Claus EB, Olson SH, Johansen C, Wrensch MR, Melin B, Jenkins RB, Sanson M, Bondy ML, Houlston RS.

Cancer Res. 2019 Feb 1. pii: canres.2888.2018. doi: 10.1158/0008-5472.CAN-18-2888. [Epub ahead of print]

PMID:
30709929
3.

The molecular landscape of glioma in patients with Neurofibromatosis 1.

D'Angelo F, Ceccarelli M, Tala, Garofano L, Zhang J, Frattini V, Caruso FP, Lewis G, Alfaro KD, Bauchet L, Berzero G, Cachia D, Cangiano M, Capelle L, de Groot J, DiMeco F, Ducray F, Farah W, Finocchiaro G, Goutagny S, Kamiya-Matsuoka C, Lavarino C, Loiseau H, Lorgis V, Marras CE, McCutcheon I, Nam DH, Ronchi S, Saletti V, Seizeur R, Slopis J, Suñol M, Vandenbos F, Varlet P, Vidaud D, Watts C, Tabar V, Reuss DE, Kim SK, Meyronet D, Mokhtari K, Salvador H, Bhat KP, Eoli M, Sanson M, Lasorella A, Iavarone A.

Nat Med. 2019 Jan;25(1):176-187. doi: 10.1038/s41591-018-0263-8. Epub 2018 Dec 10.

PMID:
30531922
4.

Developmental venous anomaly in adult patients with diffuse glioma: A clinically relevant coexistence?

Roux A, Edjlali M, Porelli S, Tauziede-Espariat A, Zanello M, Dezamis E, Zah-Bi G, Sanson M, Puget S, Capelle L, Varlet P, Oppenheim C, Pallud J.

Neurology. 2019 Jan 1;92(1):e55-e62. doi: 10.1212/WNL.0000000000006690. Epub 2018 Nov 30.

PMID:
30504430
5.

The clinical use of IDH1 and IDH2 mutations in gliomas.

Picca A, Berzero G, Di Stefano AL, Sanson M.

Expert Rev Mol Diagn. 2018 Nov 14:1-11. doi: 10.1080/14737159.2018.1548935. [Epub ahead of print]

PMID:
30427756
6.

Current and future tools for determination and monitoring of isocitrate dehydrogenase status in gliomas.

Picca A, Di Stefano AL, Sanson M.

Curr Opin Neurol. 2018 Dec;31(6):727-732. doi: 10.1097/WCO.0000000000000617.

PMID:
30239358
7.

Vemurafenib and cobimetinib overcome resistance to vemurafenib in BRAF-mutant ganglioglioma.

Touat M, Gratieux J, Condette Auliac S, Sejean K, Aldea S, Savatovsky J, Perkins G, Blons H, Ligon KL, Idbaih A, Hollebecque A, Gimenez-Roqueplo AP, Laurent-Puig P, Sanson M, Villa C, Di Stefano AL.

Neurology. 2018 Sep 11;91(11):523-525. doi: 10.1212/WNL.0000000000006171. Epub 2018 Aug 17. No abstract available.

PMID:
30120137
8.

Interactions between tumor-associated macrophages and tumor cells in glioblastoma: unraveling promising targeted therapies.

Morisse MC, Jouannet S, Dominguez-Villar M, Sanson M, Idbaih A.

Expert Rev Neurother. 2018 Sep;18(9):729-737. doi: 10.1080/14737175.2018.1510321. Epub 2018 Aug 22.

PMID:
30099909
9.

A recurrent point mutation in PRKCA is a hallmark of chordoid gliomas.

Rosenberg S, Simeonova I, Bielle F, Verreault M, Bance B, Le Roux I, Daniau M, Nadaradjane A, Gleize V, Paris S, Marie Y, Giry M, Polivka M, Figarella-Branger D, Aubriot-Lorton MH, Villa C, Vasiljevic A, Lechapt-Zalcman E, Kalamarides M, Sharif A, Mokhtari K, Pagnotta SM, Iavarone A, Lasorella A, Huillard E, Sanson M.

Nat Commun. 2018 Jun 18;9(1):2371. doi: 10.1038/s41467-018-04622-w.

10.

Transcriptomic immune profiling of ovarian cancers in paraneoplastic cerebellar degeneration associated with anti-Yo antibodies.

Vialatte de Pémille C, Berzero G, Small M, Psimaras D, Giry M, Daniau M, Sanson M, Delattre JY, Honnorat J, Desestret V, Alentorn A.

Br J Cancer. 2018 Jul;119(1):105-113. doi: 10.1038/s41416-018-0125-7. Epub 2018 Jun 14.

PMID:
29899393
11.

FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomas.

Picca A, Berzero G, Bielle F, Touat M, Savatovsky J, Polivka M, Trisolini E, Meunier S, Schmitt Y, Idbaih A, Hoang-Xuan K, Delattre JY, Mokhtari K, Di Stefano AL, Sanson M.

Neurology. 2018 Jun 5;90(23):e2086-e2094. doi: 10.1212/WNL.0000000000005658. Epub 2018 May 4.

PMID:
29728520
12.

Pazopanib efficacy in recurrent central nervous system hemangiopericytomas.

Apra C, Alentorn A, Mokhtari K, Kalamarides M, Sanson M.

J Neurooncol. 2018 Sep;139(2):369-372. doi: 10.1007/s11060-018-2870-0. Epub 2018 Apr 26.

13.

Correction to: ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma.

Dréan A, Rosenberg S, Lejeune FX, Goli L, Nadaradjane AA, Guehennec J, Schmitt C, Verreault M, Bielle F, Mokhtari K, Sanson M, Carpentier A, Delattre JY, Idbaih A.

J Neurooncol. 2018 Jul;138(3):487. doi: 10.1007/s11060-018-2830-8.

PMID:
29549621
14.

Impact of atopy on risk of glioma: a Mendelian randomisation study.

Disney-Hogg L, Cornish AJ, Sud A, Law PJ, Kinnersley B, Jacobs DI, Ostrom QT, Labreche K, Eckel-Passow JE, Armstrong GN, Claus EB, Il'yasova D, Schildkraut J, Barnholtz-Sloan JS, Olson SH, Bernstein JL, Lai RK, Schoemaker MJ, Simon M, Hoffmann P, Nöthen MM, Jöckel KH, Chanock S, Rajaraman P, Johansen C, Jenkins RB, Melin BS, Wrensch MR, Sanson M, Bondy ML, Houlston RS.

BMC Med. 2018 Mar 15;16(1):42. doi: 10.1186/s12916-018-1027-5.

15.

Influence of obesity-related risk factors in the aetiology of glioma.

Disney-Hogg L, Sud A, Law PJ, Cornish AJ, Kinnersley B, Ostrom QT, Labreche K, Eckel-Passow JE, Armstrong GN, Claus EB, Il'yasova D, Schildkraut J, Barnholtz-Sloan JS, Olson SH, Bernstein JL, Lai RK, Swerdlow AJ, Simon M, Hoffmann P, Nöthen MM, Jöckel KH, Chanock S, Rajaraman P, Johansen C, Jenkins RB, Melin BS, Wrensch MR, Sanson M, Bondy ML, Houlston RS.

Br J Cancer. 2018 Apr;118(7):1020-1027. doi: 10.1038/s41416-018-0009-x. Epub 2018 Mar 13.

PMID:
29531326
16.

ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma.

Dréan A, Rosenberg S, Lejeune FX, Goli L, Nadaradjane AA, Guehennec J, Schmitt C, Verreault M, Bielle F, Mokhtari K, Sanson M, Carpentier A, Delattre JY, Idbaih A.

J Neurooncol. 2018 Jul;138(3):479-486. doi: 10.1007/s11060-018-2819-3. Epub 2018 Mar 8. Erratum in: J Neurooncol. 2018 Mar 16;:.

PMID:
29520610
17.

Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci.

Labreche K, Kinnersley B, Berzero G, Di Stefano AL, Rahimian A, Detrait I, Marie Y, Grenier-Boley B, Hoang-Xuan K, Delattre JY, Idbaih A, Houlston RS, Sanson M.

Acta Neuropathol. 2018 May;135(5):743-755. doi: 10.1007/s00401-018-1825-z. Epub 2018 Feb 19.

18.

Current therapeutic approaches to diffuse grade II and III gliomas.

Picca A, Berzero G, Sanson M.

Ther Adv Neurol Disord. 2018 Jan 17;11:1756285617752039. doi: 10.1177/1756285617752039. eCollection 2018.

19.

Mendelian randomisation study of the relationship between vitamin D and risk of glioma.

Takahashi H, Cornish AJ, Sud A, Law PJ, Kinnersley B, Ostrom QT, Labreche K, Eckel-Passow JE, Armstrong GN, Claus EB, Ll'yasova D, Schildkraut J, Barnholtz-Sloan JS, Olson SH, Bernstein JL, Lai RK, Schoemaker MJ, Simon M, Hoffmann P, Nöthen MM, Jöckel KH, Chanock S, Rajaraman P, Johansen C, Jenkins RB, Melin BS, Wrensch MR, Sanson M, Bondy ML, Turnbull C, Houlston RS.

Sci Rep. 2018 Feb 5;8(1):2339. doi: 10.1038/s41598-018-20844-w.

20.

SFE/SFEDP adrenal insufficiency French consensus: Introduction and handbook.

Reznik Y, Barat P, Bertherat J, Bouvattier C, Castinetti F, Chabre O, Chanson P, Cortet C, Delemer B, Goichot B, Gruson D, Guignat L, Proust-Lemoine E, Sanson MR, Reynaud R, Boustani DS, Simon D, Tabarin A, Zenaty D.

Ann Endocrinol (Paris). 2018 Feb;79(1):1-22. doi: 10.1016/j.ando.2017.12.001. Epub 2018 Jan 12.

21.

A metabolic function of FGFR3-TACC3 gene fusions in cancer.

Frattini V, Pagnotta SM, Tala, Fan JJ, Russo MV, Lee SB, Garofano L, Zhang J, Shi P, Lewis G, Sanson H, Frederick V, Castano AM, Cerulo L, Rolland DCM, Mall R, Mokhtari K, Elenitoba-Johnson KSJ, Sanson M, Huang X, Ceccarelli M, Lasorella A, Iavarone A.

Nature. 2018 Jan 11;553(7687):222-227. doi: 10.1038/nature25171. Epub 2018 Jan 3.

22.

Antineoplastic agents exacerbating Charcot Marie Tooth disease: red flags to avoid permanent disability.

Ibañez-Juliá MJ, Berzero G, Reyes-Botero G, Maisonobe T, Lenglet T, Slim M, Louis S, Balaguer A, Sanson M, Le Guern E, Latour P, Ricard D, Stojkovic T, Psimaras D.

Acta Oncol. 2018 Mar;57(3):403-411. doi: 10.1080/0284186X.2017.1415462. Epub 2017 Dec 15.

PMID:
29243538
23.

Progestin-associated shift of meningioma mutational landscape.

Peyre M, Gaillard S, de Marcellus C, Giry M, Bielle F, Villa C, Boch AL, Loiseau H, Baussart B, Cazabat L, Raffin-Sanson ML, Sanson M, Kalamarides M.

Ann Oncol. 2018 Mar 1;29(3):681-686. doi: 10.1093/annonc/mdx763.

PMID:
29206892
24.

Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy.

Branzoli F, Di Stefano AL, Capelle L, Ottolenghi C, Valabrègue R, Deelchand DK, Bielle F, Villa C, Baussart B, Lehéricy S, Sanson M, Marjanska M.

Neuro Oncol. 2018 Jun 18;20(7):907-916. doi: 10.1093/neuonc/nox214.

PMID:
29126125
25.

Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular features.

Bielle F, Di Stefano AL, Meyronet D, Picca A, Villa C, Bernier M, Schmitt Y, Giry M, Rousseau A, Figarella-Branger D, Maurage CA, Uro-Coste E, Lasorella A, Iavarone A, Sanson M, Mokhtari K.

Brain Pathol. 2018 Sep;28(5):674-683. doi: 10.1111/bpa.12563. Epub 2017 Nov 21.

PMID:
28976058
26.

Glioblastoma targeted therapy: updated approaches from recent biological insights.

Touat M, Idbaih A, Sanson M, Ligon KL.

Ann Oncol. 2017 Jul 1;28(7):1457-1472. doi: 10.1093/annonc/mdx106. Review.

27.

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.

van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM.

Lancet. 2017 Oct 7;390(10103):1645-1653. doi: 10.1016/S0140-6736(17)31442-3. Epub 2017 Aug 8. Erratum in: Lancet. 2017 Oct 7;390(10103):1644.

28.

Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients.

Quillien V, Lavenu A, Ducray F, Meyronet D, Chinot O, Fina F, Sanson M, Carpentier C, Karayan-Tapon L, Rivet P, Entz-Werle N, Legrain M, Zalcman EL, Levallet G, Escande F, Ramirez C, Chiforeanu D, Vauleon E, Figarella-Branger D.

Cancer Biomark. 2017 Dec 6;20(4):435-441. doi: 10.3233/CBM-170191.

29.

Diffuse midline skull base meningiomas: identification of a rare and aggressive subgroup of meningiomas.

Peyre M, Feuvret L, Sanson M, Navarro S, Boch AL, Loiseau H, Kalamarides M.

J Neurooncol. 2017 Jul;133(3):633-639. doi: 10.1007/s11060-017-2480-2. Epub 2017 May 23.

PMID:
28536991
30.

Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors.

Melin BS, Barnholtz-Sloan JS, Wrensch MR, Johansen C, Il'yasova D, Kinnersley B, Ostrom QT, Labreche K, Chen Y, Armstrong G, Liu Y, Eckel-Passow JE, Decker PA, Labussière M, Idbaih A, Hoang-Xuan K, Di Stefano AL, Mokhtari K, Delattre JY, Broderick P, Galan P, Gousias K, Schramm J, Schoemaker MJ, Fleming SJ, Herms S, Heilmann S, Nöthen MM, Wichmann HE, Schreiber S, Swerdlow A, Lathrop M, Simon M, Sanson M, Andersson U, Rajaraman P, Chanock S, Linet M, Wang Z, Yeager M; GliomaScan Consortium, Wiencke JK, Hansen H, McCoy L, Rice T, Kosel ML, Sicotte H, Amos CI, Bernstein JL, Davis F, Lachance D, Lau C, Merrell RT, Shildkraut J, Ali-Osman F, Sadetzki S, Scheurer M, Shete S, Lai RK, Claus EB, Olson SH, Jenkins RB, Houlston RS, Bondy ML.

Nat Genet. 2017 May;49(5):789-794. doi: 10.1038/ng.3823. Epub 2017 Mar 27.

31.

Epigenetics: a new tool for meningioma management?

Sanson M, Kalamarides M.

Lancet Oncol. 2017 May;18(5):569-570. doi: 10.1016/S1470-2045(17)30153-5. Epub 2017 Mar 15. No abstract available.

PMID:
28314686
32.

Melanocortin Receptor-4 Gene Polymorphisms in Glioblastoma Patients Treated with Concomitant Radio-Chemotherapy.

Pasqualetti F, Orlandi P, Simeon V, Cantarella M, Giuliani D, Di Desidero T, Gonnelli A, Delishaj D, Lombardi G, Sechi A, Sanson M, Zagonel V, Paiar F, Danesi R, Guarini S, Bocci G.

Mol Neurobiol. 2018 Feb;55(2):1396-1404. doi: 10.1007/s12035-017-0414-9. Epub 2017 Feb 1.

PMID:
28150230
33.

SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.

Boetto J, Bielle F, Sanson M, Peyre M, Kalamarides M.

Neuro Oncol. 2017 Mar 1;19(3):345-351. doi: 10.1093/neuonc/now276.

34.

FGFR-TACC gene fusions in human glioma.

Lasorella A, Sanson M, Iavarone A.

Neuro Oncol. 2017 Apr 1;19(4):475-483. doi: 10.1093/neuonc/now240. Review.

35.

Tumor cells with neuronal intermediate progenitor features define a subgroup of 1p/19q co-deleted anaplastic gliomas.

Bielle F, Ducray F, Mokhtari K, Dehais C, Adle-Biassette H, Carpentier C, Chanut A, Polivka M, Poggioli S, Rosenberg S, Giry M, Marie Y, Duyckaerts C, Sanson M, Figarella-Branger D, Idbaih A; Pola Network.

Brain Pathol. 2017 Sep;27(5):567-579. doi: 10.1111/bpa.12434. Epub 2016 Oct 28.

PMID:
27543943
36.

Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors.

Rosenberg S, Verreault M, Schmitt C, Guegan J, Guehennec J, Levasseur C, Marie Y, Bielle F, Mokhtari K, Hoang-Xuan K, Ligon K, Sanson M, Delattre JY, Idbaih A.

Neuro Oncol. 2017 Feb 1;19(2):219-228. doi: 10.1093/neuonc/now160.

37.

Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial.

Quillien V, Lavenu A, Ducray F, Joly MO, Chinot O, Fina F, Sanson M, Carpentier C, Karayan-Tapon L, Rivet P, Entz-Werle N, Legrain M, Zalcman EL, Levallet G, Escande F, Ramirez C, Chiforeanu D, Vauleon E, Figarella-Branger D.

Oncotarget. 2016 Sep 20;7(38):61916-61929. doi: 10.18632/oncotarget.11322.

38.

Radiation plus Chemotherapy in Low-Grade Glioma.

Touat M, Idbaih A, Sanson M.

N Engl J Med. 2016 Aug 4;375(5):489-90. doi: 10.1056/NEJMc1605897. No abstract available.

PMID:
27518678
39.

Chromosome 17p Homodisomy Is Associated With Better Outcome in 1p19q Non-Codeleted and IDH-Mutated Gliomas.

Labussière M, Rahimian A, Giry M, Boisselier B, Schmitt Y, Polivka M, Mokhtari K, Delattre JY, Idbaih A, Labreche K, Alentorn A, Sanson M.

Oncologist. 2016 Sep;21(9):1131-5. doi: 10.1634/theoncologist.2016-0003. Epub 2016 Jul 8.

40.

Clinical trial of blood-brain barrier disruption by pulsed ultrasound.

Carpentier A, Canney M, Vignot A, Reina V, Beccaria K, Horodyckid C, Karachi C, Leclercq D, Lafon C, Chapelon JY, Capelle L, Cornu P, Sanson M, Hoang-Xuan K, Delattre JY, Idbaih A.

Sci Transl Med. 2016 Jun 15;8(343):343re2. doi: 10.1126/scitranslmed.aaf6086.

PMID:
27306666
41.

Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas.

Kamoun A, Idbaih A, Dehais C, Elarouci N, Carpentier C, Letouzé E, Colin C, Mokhtari K, Jouvet A, Uro-Coste E, Martin-Duverneuil N, Sanson M, Delattre JY, Figarella-Branger D, de Reyniès A, Ducray F; POLA network.

Nat Commun. 2016 Apr 19;7:11263. doi: 10.1038/ncomms11263.

42.

Characteristics of gliomas in patients with somatic IDH mosaicism.

Bonnet C, Thomas L, Psimaras D, Bielle F, Vauléon E, Loiseau H, Cartalat-Carel S, Meyronet D, Dehais C, Honnorat J, Sanson M, Ducray F.

Acta Neuropathol Commun. 2016 Mar 31;4:31. doi: 10.1186/s40478-016-0302-y.

43.

Adenovirus related lymphohistiocytic hemophagocytosis: Case report and literature review.

Mellon G, Henry B, Aoun O, Boutolleau D, Laparra A, Mayaux J, Sanson M, Caumes E.

J Clin Virol. 2016 May;78:53-6. doi: 10.1016/j.jcv.2016.03.011. Epub 2016 Mar 10. Review.

PMID:
26985594
44.

Angiopoietin-2 May Be Involved in the Resistance to Bevacizumab in Recurrent Glioblastoma.

Labussière M, Cheneau C, Prahst C, Gállego Pérez-Larraya J, Farina P, Lombardi G, Mokhtari K, Rahimian A, Delattre JY, Eichmann A, Sanson M.

Cancer Invest. 2016;34(1):39-44. doi: 10.3109/07357907.2015.1088948. Epub 2016 Jan 6. Erratum in: Cancer Invest. 2017 Feb 7;35(2):142.

PMID:
26735326
45.

Quantifying the heritability of glioma using genome-wide complex trait analysis.

Kinnersley B, Mitchell JS, Gousias K, Schramm J, Idbaih A, Labussière M, Marie Y, Rahimian A, Wichmann HE, Schreiber S, Hoang-Xuan K, Delattre JY, Nöthen MM, Mokhtari K, Lathrop M, Bondy M, Simon M, Sanson M, Houlston RS.

Sci Rep. 2015 Dec 2;5:17267. doi: 10.1038/srep17267.

46.

TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas.

Nencha U, Rahimian A, Giry M, Sechi A, Mokhtari K, Polivka M, Schmitt Y, Di Stefano AL, Alentorn A, Labussière M, Sanson M.

J Neurooncol. 2016 Feb;126(3):441-6. doi: 10.1007/s11060-015-1999-3. Epub 2015 Nov 25.

PMID:
26608520
47.

Dramatic worsening of adult-onset X-linked adrenoleukodystrophy after head trauma.

Bouquet F, Dehais C, Sanson M, Lubetzki C, Louapre C.

Neurology. 2015 Dec 1;85(22):1991-3. doi: 10.1212/WNL.0000000000002173. Epub 2015 Nov 4. No abstract available.

PMID:
26537054
48.

Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas.

Verreault M, Schmitt C, Goldwirt L, Pelton K, Haidar S, Levasseur C, Guehennec J, Knoff D, Labussière M, Marie Y, Ligon AH, Mokhtari K, Hoang-Xuan K, Sanson M, Alexander BM, Wen PY, Delattre JY, Ligon KL, Idbaih A.

Clin Cancer Res. 2016 Mar 1;22(5):1185-96. doi: 10.1158/1078-0432.CCR-15-1015. Epub 2015 Oct 19. Erratum in: Clin Cancer Res. 2016 May 1;22(9):2313.

49.

LRP1B deletion is associated with poor outcome for glioblastoma patients.

Tabouret E, Labussière M, Alentorn A, Schmitt Y, Marie Y, Sanson M.

J Neurol Sci. 2015 Nov 15;358(1-2):440-3. doi: 10.1016/j.jns.2015.09.345. Epub 2015 Sep 11.

PMID:
26428308
50.

Genome-wide association study identifies multiple susceptibility loci for glioma.

Kinnersley B, Labussière M, Holroyd A, Di Stefano AL, Broderick P, Vijayakrishnan J, Mokhtari K, Delattre JY, Gousias K, Schramm J, Schoemaker MJ, Fleming SJ, Herms S, Heilmann S, Schreiber S, Wichmann HE, Nöthen MM, Swerdlow A, Lathrop M, Simon M, Bondy M, Sanson M, Houlston RS.

Nat Commun. 2015 Oct 1;6:8559. doi: 10.1038/ncomms9559.

Supplemental Content

Loading ...
Support Center